393 related articles for article (PubMed ID: 12632082)
1. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
[TBL] [Abstract][Full Text] [Related]
2. Effect of Bcl-2 antisense oligonucleotide on drug-sensitivity in association with apoptosis in undifferentiated thyroid carcinoma.
Kim R; Tanabe K; Uchida Y; Emi M; Toge T
Int J Mol Med; 2003 Jun; 11(6):799-804. PubMed ID: 12736725
[TBL] [Abstract][Full Text] [Related]
3. Modulation of tamoxifen sensitivity by antisense Bcl-2 and trastuzumab in breast carcinoma cells.
Kim R; Tanabe K; Emi M; Uchida Y; Toge T
Cancer; 2005 May; 103(10):2199-207. PubMed ID: 15830342
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
Rait AS; Pirollo KF; Rait V; Krygier JE; Xiang L; Chang EH
Cancer Gene Ther; 2001 Oct; 8(10):728-39. PubMed ID: 11687896
[TBL] [Abstract][Full Text] [Related]
5. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
6. Death receptor-dependent and -independent pathways in anticancer drug-induced apoptosis of breast cancer cells.
Kim R; Tanabe K; Emi M; Uchida Y; Toge T
Oncol Rep; 2003; 10(6):1925-30. PubMed ID: 14534720
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of antisense bcl-2 as a chemosensitizer for patients with gastric carcinoma.
Kim R; Emi M; Tanabe K; Toge T
Cancer; 2004 Nov; 101(10):2177-86. PubMed ID: 15476281
[TBL] [Abstract][Full Text] [Related]
8. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
9. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
10. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
12. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic potential of antisense (AS) Bcl-2 as a chemosensitizer for patients with gastric and breast carcinoma].
Kim R; Emi M; Matsuura K; Tanabe K
Gan To Kagaku Ryoho; 2005 Oct; 32(11):1540-5. PubMed ID: 16315863
[TBL] [Abstract][Full Text] [Related]
14. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
[TBL] [Abstract][Full Text] [Related]
15. Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.
Sun J; Xu Y; Song S; Wu Z; Duan H
Pharm Biol; 2011 Nov; 49(11):1167-72. PubMed ID: 22014264
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy against Bcl-2-related proteins in breast cancer cells.
Emi M; Kim R; Tanabe K; Uchida Y; Toge T
Breast Cancer Res; 2005; 7(6):R940-52. PubMed ID: 16280040
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Miyake H; Nelson C; Rennie PS; Gleave ME
Cancer Res; 2000 May; 60(9):2547-54. PubMed ID: 10811138
[TBL] [Abstract][Full Text] [Related]
18. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review).
Kim R; Tanabe K; Uchida Y; Osaki A; Toge T
Oncol Rep; 2002; 9(1):3-9. PubMed ID: 11748447
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells.
Schwartz GK; Farsi K; Maslak P; Kelsen DP; Spriggs D
Clin Cancer Res; 1997 Sep; 3(9):1467-72. PubMed ID: 9815832
[TBL] [Abstract][Full Text] [Related]
20. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]